NCT04478448View on ClinicalTrials.gov

Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

August 20, 2020

Study Completion Date

August 26, 2020

Conditions
Healthy
Interventions
DRUG

Flupirava

1 tablet contains 200 mg Favipiravir

DRUG

Avigan

1 tablet contains 200 mg Favipiravir

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

All Listed Sponsors
collaborator

European Egyptian Pharmaceutical Industries

INDUSTRY

lead

Genuine Research Center, Egypt

INDUSTRY

NCT04478448 - Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan) | Biotech Hunter | Biotech Hunter